Thomas Hutson, DO, PharmD

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.

Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.

An overview of the treatment options available for patients with renal cell carcinoma (RCC).